00:08 , Aug 14, 2019 |  BC Extra  |  Financial News

$60M B round to propel Landos through Phase II IBD trials

Landos' $60 million series B will enable it to complete two Phase II trials, one each in ulcerative colitis and Crohn's disease, of lead product BT-11. Chairman, President and CEO Josep Bassaganya-Riera told BioCentury he...
23:02 , Aug 6, 2019 |  BC Extra  |  Company News

Newly launched LUCA planning to tackle infections in women

Seed Health launched LUCA Tuesday with $2.8 million in seed funding to develop living medicines to fight infections in women. It is the first biotech to emerge from the biotherapeutics accelerator. The funding will take...
00:02 , Jun 19, 2019 |  BC Extra  |  Company News

June 18 Company Quick Takes: Sino-Akeso JV, plus Oxford Drug Design, Be The Match and more

CTTQ, Akeso form JV to develop PD-1 mAb  The Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ) subsidiary of Sino Biopharmaceutical Ltd. (HKEX:1177) formed a 50/50 joint venture with Akeso Biopharma Inc. (Zhongshan, China) to...
21:21 , Jun 14, 2019 |  BioCentury  |  Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
10:52 , Jun 7, 2019 |  BC Extra  |  Company News

As Sanofi enters growth phase, Novartis exec Hudson to take the helm

Novartis has lost one executive from each of its Innovative Medicines units in the span of three days, now that Sanofi has named seasoned British sales and marketing executive Paul Hudson as the successor to...
00:51 , Jun 7, 2019 |  BC Innovations  |  Finance

Alexandria parlays growing life sciences real estate holdings into a flurry of VC deals

Alexandria has been leveraging its growing life sciences real estate revenues and relationships with leading VC firms to become the most prolific biotech investor, and it shows no signs of slowing down. Over its 25-year...
00:51 , May 31, 2019 |  BC Innovations  |  Targets & Mechanisms

Targeting cancer evolution offers a way to foil drug resistance

A growing crop of researchers and companies are tackling cancer drug resistance by preempting tumors’ tendencies to adapt, rather than responding to resistance after it develops. Though still in their infancy, these therapies could get...
22:37 , May 29, 2019 |  BC Extra  |  Company News

CHMP against Emmaus' sickle cell therapy, Taiwan Liposome's doxorubicin

EMA's CHMP issued several opinions Wednesday, including a negative opinion for Emmaus' sickle cell disease therapy, and on re-examination, a negative recommendation for Taiwan Liposome's breast and ovarian cancer treatment. The agency recommended against approval...
20:49 , May 24, 2019 |  BioCentury  |  Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
20:45 , May 24, 2019 |  BioCentury  |  Finance

Europe: Some spots hotter than others

Led by the U.K., various regions in Europe are raising their profile as hotspots of innovation. But as other areas lose ground, local VCs are raising fresh capital and building the infrastructure needed to boost...